Armen A Ghazarian1, Scott P Kelly1, Sean F Altekruse2, Philip S Rosenberg1, Katherine A McGlynn1. 1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. 2. Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Abstract
BACKGROUND: Testicular germ cell tumors (TGCTs) are rare tumors in the general population but are the most commonly occurring malignancy among males between ages 15 and 44 years in the United States (US). Although non-Hispanic whites (NHWs) have the highest incidence in the US, rates among Hispanics have increased the most in recent years. To forecast what these incidence rates may be in the future, an analysis of TGCT incidence in the Surveillance, Epidemiology, and End Results program and the National Program of Cancer Registries was conducted. METHODS: TGCT incidence data among males ages 15 to 59 years for the years 1999 to 2012 were obtained from 39 US cancer registries. Incidence rates through 2026 were forecast using age-period-cohort models stratified by race/ethnicity, histology (seminoma, nonseminoma), and age. RESULTS: Between 1999 and 2012, TGCT incidence rates, both overall and by histology, were highest among NHWs, followed by Hispanics, Asian/Pacific Islanders, and non-Hispanic blacks. Between 2013 and 2026, rates among Hispanics were forecast to increase annually by 3.96% (95% confidence interval, 3.88%-4.03%), resulting in the highest rate of increase of any racial/ethnic group. By 2026, the highest TGCT rates in the US will be among Hispanics because of increases in both seminomas and nonseminomas. Rates among NHWs will slightly increase, whereas rates among other groups will slightly decrease. CONCLUSIONS: By 2026, Hispanics will have the highest rate of TGCT of any racial/ethnic group in the US because of the rising incidence among recent birth cohorts. Reasons for the increase in younger Hispanics merit further exploration. Cancer 2017;123:2320-2328.
BACKGROUND:Testicular germ cell tumors (TGCTs) are rare tumors in the general population but are the most commonly occurring malignancy among males between ages 15 and 44 years in the United States (US). Although non-Hispanic whites (NHWs) have the highest incidence in the US, rates among Hispanics have increased the most in recent years. To forecast what these incidence rates may be in the future, an analysis of TGCT incidence in the Surveillance, Epidemiology, and End Results program and the National Program of Cancer Registries was conducted. METHODS: TGCT incidence data among males ages 15 to 59 years for the years 1999 to 2012 were obtained from 39 US cancer registries. Incidence rates through 2026 were forecast using age-period-cohort models stratified by race/ethnicity, histology (seminoma, nonseminoma), and age. RESULTS: Between 1999 and 2012, TGCT incidence rates, both overall and by histology, were highest among NHWs, followed by Hispanics, Asian/Pacific Islanders, and non-Hispanic blacks. Between 2013 and 2026, rates among Hispanics were forecast to increase annually by 3.96% (95% confidence interval, 3.88%-4.03%), resulting in the highest rate of increase of any racial/ethnic group. By 2026, the highest TGCT rates in the US will be among Hispanics because of increases in both seminomas and nonseminomas. Rates among NHWs will slightly increase, whereas rates among other groups will slightly decrease. CONCLUSIONS: By 2026, Hispanics will have the highest rate of TGCT of any racial/ethnic group in the US because of the rising incidence among recent birth cohorts. Reasons for the increase in younger Hispanics merit further exploration. Cancer 2017;123:2320-2328.
Keywords:
Incidence; North American Association of Central Cancer Registries (NAACCR); ethnic groups; testicular cancer; testicular gem cell tumor (TGCT); trends
Authors: Gillian P Crockford; Rachel Linger; Sarah Hockley; Darshna Dudakia; Lola Johnson; Robert Huddart; Kathy Tucker; Michael Friedlander; Kelly-Anne Phillips; David Hogg; Michael A S Jewett; Radka Lohynska; Gedske Daugaard; Stéphane Richard; Agnes Chompret; Catherine Bonaïti-Pellié; Axel Heidenreich; Peter Albers; Edith Olah; Lajos Geczi; Istvan Bodrogi; Wilma J Ormiston; Peter A Daly; Parry Guilford; Sophie D Fosså; Ketil Heimdal; Sergei A Tjulandin; Ludmila Liubchenko; Hans Stoll; Walter Weber; David Forman; Timothy Oliver; Lawrence Einhorn; Mary McMaster; Joan Kramer; Mark H Greene; Barbara L Weber; Katherine L Nathanson; Victoria Cortessis; Douglas F Easton; D Timothy Bishop; Michael R Stratton; Elizabeth A Rapley Journal: Hum Mol Genet Date: 2006-01-11 Impact factor: 6.150
Authors: Lorenzo Richiardi; Rino Bellocco; Hans-Olov Adami; Anna Torrång; Lotti Barlow; Timo Hakulinen; Mati Rahu; Aivars Stengrevics; Hans Storm; Steinar Tretli; Juozas Kurtinaitis; Jerzy E Tyczynski; Olof Akre Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-12 Impact factor: 4.254
Authors: Katherine A McGlynn; Susan S Devesa; Alice J Sigurdson; Linda M Brown; Lilian Tsao; Robert E Tarone Journal: Cancer Date: 2003-01-01 Impact factor: 6.860
Authors: Armen A Ghazarian; Britton Trabert; Kim Robien; Barry I Graubard; Katherine A McGlynn Journal: Environ Res Date: 2018-02-23 Impact factor: 6.498
Authors: Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga Journal: Nat Rev Dis Primers Date: 2018-10-05 Impact factor: 52.329
Authors: Michael J Hwang; Ameer Hamza; Miao Zhang; Shi-Ming Tu; Louis L Pisters; Bogdan Czerniak; Charles C Guo Journal: Am J Surg Pathol Date: 2022-01-01 Impact factor: 6.298